On December 25, the four companies announced the withdrawal of two IPOs on the same day.
Nantong Guanyouda Magnetic Industry Co., Ltd. *** referred to as "Guanyouda") and Shenzhen Aibeke Precision Industry Co., Ltd. *** referred to as "Aibeke") The IPO review status of the GEM of the two companies was changed to "terminated (withdrawn)". Beijing Huamai Tech Medical Device Co., Ltd. (hereinafter referred to as "Huamai Tech") and Chongqing Tianjian Inertial Technology Co., Ltd. (hereinafter referred to as "Tianjian Inertia") changed the IPO review status of the Science and Technology Innovation Board to "terminated".
Mainly engaged in magnetic materials
According to the prospectus, Guanyouda has been deeply engaged in the field of manganese-zinc soft ferrite materials for a long time, specializing in the research and development, production and sales of manganese-zinc soft ferrite materials, and its products cover two series of magnetic powders and cores of power and high conductivity. According to the data of the Magnetic Materials Branch of the China Electronic Materials Industry Association, the output of manganese-zinc soft ferrite materials from 2020 to 2022 ranked among the top three in the same industry in China. In 2022, the output of Guanyouda soft ferrite magnetic powder will be 42,39647 tons, the output of soft ferrite cores is 1251578 tons.
It is worth mentioning that Guanyouda is the vice chairman unit of the Magnetic Materials Branch of the China Electronic Materials Industry Association, and the fourth top ten professional enterprises in the magnetic materials industry of China's electronic materials industry. In addition, Guanyouda gives full play to the synergistic advantages of the vertical layout of the industrial chain, and through years of product innovation and process improvement, it provides high-performance magnetic materials for various electronic magnetic components to achieve functions such as power transmission, power conversion and signal screening, which can meet the diversified and differentiated needs of household appliances, consumer electronics, photovoltaic power generation, automotive electronics and other fields, and has become one of the few manufacturers in the industry that can scale up the most stable quality and excellent performance of soft ferrite materials.
In terms of customers, with its leading scale and excellent product performance, Guanyouda's core products have entered the first-class system of many well-known end customers such as Midea, Gree, Samsung, LG Electronics and so on through electronic magnetic component customers. In Guanyouda's view, stable and long-term high-quality customer resources reflect the company's core competitiveness gradually accumulated in the field of focus and segmentation, and lay a solid foundation for the company's future market share expansion.
In terms of performance, Guanyouda's revenue from 2021 to the first half of 2023 was 9700 million yuan, 68.7 billion yuan and 33.8 billion yuan, and the net profit in the same period was 7309070,000 yuan, 5125780,000 yuan and 2950420,000 yuan.
In this IPO, Guanyouda originally planned to raise 46.6 billion yuan, for an annual output of 120,000 tons of manganese-zinc ferrite core expansion project, with an annual output of 240,000 tons of high-performance magnetic powder production project, R&D center project, supplementary working capital.
In June this year, the IPO of Guanyouda GEM was accepted by the exchange, and then the company was sent three rounds of inquiries since July, of which the first two rounds of inquiries The company has disclosed the content of the reply. On December 25, the Shenzhen Stock Exchange announced that on December 21, Guanyouda applied for the withdrawal of the issuance and listing application documents. In accordance with the regulations, the Exchange has decided to terminate the review of its initial public offering** and listing on the GEM.
The original plan was to raise nearly 700 million yuan
On the same day, Aibeco, which withdrew its GEM IPO, is a machine tool functional component enterprise specializing in R&D, manufacturing, sales and related supporting services of high-precision spindles, which mainly include electric spindles and mechanical spindles, which are widely used in various CNC machine tools, including machining centers, engraving machines, lathes, milling machines and grinding machines.
As a key functional component that affects the machining accuracy, processing quality and stability of the "industrial machine tool", Aibek spindle products have the characteristics of high speed, high power, high torque and large outer diameter, and have the performance of high precision, high stiffness, low temperature rise and low vibration. The company is a national high-tech enterprise and a specialized and special new enterprise in Shenzhen, and has now developed into one of the leading high-precision machine tool spindle design and manufacturers in China.
Aibeco has been deeply involved in the spindle industry for a long time, and is committed to realizing the import substitution and product technology innovation of CNC machine tool spindles. After years of technology iteration and business accumulation, the company has mastered a number of core technologies and processes, established a R&D, manufacturing and process system covering spindle, high-speed and high-performance motor design, precision parts production and assembly, and formed more than 500 different types of electric spindles and mechanical spindles product pedigree, product accuracy, stiffness, reliability and other performance have been continuously improved, and the large-scale production and sales of electric spindles and mechanical spindles have been realized.
During the reporting period, Aibeco's main customers included Qiaofeng Intelligence, Taiyi Yingtuo, Beishen Machinery, Lens Technology, Deyang CNC, Huizhuan Technology, Huadong Heavy Machinery and Han's Laser.
In terms of performance, from 2020 to 2022, Aibeco achieved revenue of 14.1 billion yuan, 27.4 billion and 26.9 billion yuan, and the net profit in the same period was 1718070,000 yuan, 5410750,000 yuan and 5241690,000 yuan.
In this IPO, Aibeco originally planned to raise 6800 million yuan, respectively, invested in the production and construction project of high-precision CNC spindle, the construction project of R&D center and the replenishment of working capital.
In June this year, the IPO of Aibeke GEM was accepted by the exchange, and then it was questioned in July, but it did not disclose a reply until the IPO was withdrawn. On December 25, the Shenzhen Stock Exchange announced that on December 22, Aibeco applied for the withdrawal of the issuance of listing application documents. In accordance with the regulations, the Exchange has decided to terminate the review of its initial public offering** and listing on the GEM.
No profitability has been achieved yet
According to the prospectus, Huamai Tech is a high-tech enterprise focusing on the R&D and application of innovative products in the field of vascular diseases in China, and its main business is the R&D, production and sales of medical device products in the fields of aorta, peripheral and coronary artery, neurointerventional and access.
Huamai Tech has been deeply engaged in the field of vascular diseases for many years, and on the basis of the innovation and application of aortic products and products, and based on its own accumulated experience in vascular diseases, it has gradually expanded its layout to the fields of peripheral and coronary artery, neurointervention and access, so as to achieve business coverage of whole vascular diseases.
In the field of endovascular aortic intervention, Huamai Tech has developed the world's first thoracic aortic stent graft product specifically for the repair of short-anchored aortic dissection** according to the frequent characteristics of aortic dissection that distinguish Chinese people from Europe and the United States, filling the international clinical gap. In view of the complex and difficult abdominal aortic aneurysm lesions that occur frequently in Chinese patients, the company has innovatively developed abdominal aortic stent graft products suitable for short anchoring area and large angle aneurysm, which solves the world-class clinical problem of limited stent anchoring area and effectively expands the indications of endovascular intervention.
As of the signing date of the prospectus, 8 products have obtained the NMPA medical device product registration certificate, and 2 products have obtained the EU CE certification. The company's products have covered more than 400 hospitals in 31 provinces, autonomous regions and municipalities directly under the central government, including Beijing Anzhen Hospital affiliated to Capital Medical University, Zhongshan Hospital affiliated to Fudan University, the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) and other well-known tertiary hospitals in China.
It is worth noting that Huamai Tech has not yet achieved profitability. From 2019 to the first half of 2022, Huamai Tech's operating income was 4894440,000 yuan, 5,000170,000 yuan, 8882690,000 yuan and 6083690,000 yuan. The net profit for the same period was about -3281250,000 yuan, -12.6 billion yuan, -1200 million and -2754180,000 yuan.
Huamai Tech said that the main reason for the company's continuous loss is that the company's products have been on the market for a relatively short time, the listed products have not yet achieved large-scale commercialization, and have not formed an obvious scale effect, and the company's product project progress continues to advance and some products are carrying out clinical trials, resulting in a large investment in the company's research and development expenses during the reporting periodAt the same time, in order to achieve a long-term incentive mechanism for talents, the company implemented equity incentives for employees, resulting in higher share-based payment expenses during the reporting period.
In this IPO, Huamai Tech originally planned to raise 129.3 billion yuan, which will be used for the new production base project of high-end medical devices, the research and development project of ** medical device for vascular diseases and the replenishment of working capital.
In December last year, the IPO of Huamai Tech's Science and Technology Innovation Board was accepted by the exchange, and then the company was inquired in January this year. On December 25, the Shanghai Stock Exchange announced that due to the withdrawal of the issuance and listing application by Huamai Tech and its sponsors, the Shanghai Stock Exchange terminated its issuance and listing review in accordance with relevant regulations.
The original plan was to raise more than 900 million yuan
On the same day, Tianjian Inertia, which withdrew from the IPO of the Science and Technology Innovation Board, has been conducting professional research on gyroscopes for a long time, mainly engaged in the research and development, production and sales of inertial devices and inertial systems. Since its establishment, the company has engaged in the research of inertial devices and inertial systems such as piezoelectric gyroscopes, power-tuned gyroscopes, miniaturized power-tuned gyroscopes, fiber optic gyroscopes, MEMS gyroscopes, etc.
Tianjian inertial has long served the field of national defense industry, adhering to the development concept of taking the core components of inertial technology as the main development direction and extending to the field of navigation, guidance and control, and striving to become a first-class business in navigation, guidance and control systems in China's precision guidance industry.
During the reporting period, the main products of Tianjian inertia were miniaturized power-tuned gyroscopes and fiber optic gyroscopes. The miniaturized power-tuned gyroscope is mainly equipped with miniaturized precision guidance and seeker stabilization platform system, etc., and is widely used in airborne guidance, individual portable guidance, vehicle-mounted guidance, etcFiber optic gyroscopes are mainly used in inertial navigation systems, photoelectric stabilization platforms and other fieldsIn addition to miniaturized power-tuned gyroscopes and fiber optic gyroscopes, the company also has MEMS gyroscopes, inertial navigation systems, integrated navigation systems, navigation guidance and control integrated products (GNC) and photoelectric pods.
In terms of performance, from 2020 to 2022, the revenue of Tianjian inertia will be 15.5 billion yuan, 19.8 billion and 25.9 billion yuan, and the net profit in the same period was 4046620,000 yuan, 3258240,000 yuan and 2766960,000 yuan.
In this IPO, Sky Arrow Inertia originally planned to raise 92.6 billion yuan, which was invested in the construction project of inertial device research and production base and the replenishment of working capital.
In June this year, the IPO of Tianjian Inertial Science and Technology Innovation Board was accepted by the exchange, and then it was questioned in July, but it did not disclose a reply until the IPO was withdrawn. On December 25, the Shanghai Stock Exchange announced that due to the withdrawal of the issuance and listing application by Tianjian inertia and its sponsor, the Exchange terminated its issuance and listing review in accordance with relevant regulations.